北京义翘神州科技股份有限公司 2022 年第一季度报告全文 证券代码：301047 证券简称：义翘神州 公告编号：2022-037 北京义翘神州科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □是√否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------------|------- ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-on-year growth of 25%[18]. - The net profit for the year was RMB 300 million, an increase of 30% compared to the previous year[18]. - The company's operating revenue for 2021 was ¥965,272,540.65, a decrease of 39.53% compared to ¥1,596,293,024.87 in 2020[25]. - The net profit attributable to shareholders for 2021 was ¥720,013,671.11, down 36.15% from ¥1,127,607,535.02 in 2020[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥596,583,791.15, a decline of 46.81% compared to ¥1,121,594,021.44 in 2020[25]. - The basic earnings per share for 2021 was ¥12.7061, a decrease of 42.53% from ¥22.1100 in 2020[25]. - The company reported a net cash flow from operating activities of ¥642,617,805.03, down 41.20% from ¥1,092,937,539.00 in 2020[25]. - The revenue from COVID-19 related business was ¥605,787,520.51, accounting for 62.76% of total revenue, down 54.86% from ¥1,342,074,558.04 in 2020[107]. - The revenue from non-COVID-19 related business was ¥359,485,020.14, showing a growth of 41.41% compared to the previous year[107]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[18]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of RMB 1 billion for strategic investments[18]. - The company plans to enhance its marketing and service capabilities by expanding its customer service and logistics centers in key regions, including the Yangtze River Delta and Pearl River Delta[157]. - The company plans to focus on mergers and acquisitions to enhance its product line and technical capabilities, with some projects expected to reach cooperation or investment intentions in 2022[166]. Research and Development - The company has allocated RMB 200 million for research and development in 2022, aiming to enhance its technological capabilities[18]. - The company invested over 20 million yuan in advanced equipment, with overall R&D investment increasing by 53.99% year-on-year, enhancing its core competitiveness[91]. - The company’s R&D expenses for 2021 amounted to ¥40,129,306.95, representing a 53.99% increase compared to ¥26,059,125.31 in 2020[120]. - The company has developed a comprehensive quality management system, certified by ISO9001, ISO13485, and CNAS, ensuring product quality throughout its lifecycle[79]. - The company focuses on independent research and development, aiming to meet the demand for natural protein structures and properties in its recombinant protein offerings[68]. - The company has achieved rapid product development, exemplified by the ability to complete related protein development for COVID-19 in just six days, allowing for same-day or next-day delivery to domestic customers[47]. Product Development and Offerings - New product development includes the launch of a novel biopharmaceutical product expected to generate RMB 500 million in revenue in the first year[18]. - The company launched over 1,500 new biological reagent products in 2021, expanding its total product offerings to more than 52,000, including over 6,500 recombinant proteins and approximately 14,000 antibodies[68]. - The company has developed a product library of over 6,500 protein reagents and approximately 14,000 antibody reagents, with nearly 32,000 gene products available[94]. - The company is developing dry powder culture media to meet the increasing demand from industrial clients, as it offers lower unit costs and easier transportation compared to liquid media[158]. - The company is developing a high-affinity broad-spectrum influenza NP antibody kit, with one product already completed[124]. Customer Base and Market Demand - The company has a customer base that includes universities, research institutes, and pharmaceutical R&D enterprises, indicating a diverse market presence[69]. - The demand for customized products and services has been increasing, with the company’s customized R&D, production, and testing services showing sustained rapid growth[48]. - The company’s performance has been positively impacted by the growing need for one-stop procurement services, which require high R&D and production capabilities[46]. - The company generated 36.89% of its revenue from the U.S. market in 2021, highlighting its reliance on international markets[173]. Financial Management and Governance - The company has established a complete independent business and operational capability, with no reliance on the controlling shareholder in areas such as business operations, financial management, and human resources[182]. - The board of directors consists of 9 members, including 3 independent directors, and held 6 meetings in 2021 to ensure effective governance and decision-making[183]. - The company has a dedicated financial department with independent financial personnel and a standardized financial management system, ensuring financial independence from shareholders[194]. - The annual shareholders meeting on June 30, 2021, had a 100% investor participation rate[195]. - The meeting approved the financial budget report for 2021 and the profit distribution plan for 2020[195]. Risks and Challenges - The company has identified potential risks in supply chain disruptions and is implementing measures to mitigate these risks[6]. - The company recognizes the risk of revenue decline due to the potential decrease in demand for COVID-19 related products as the pandemic situation stabilizes[167]. - The company has faced operational risks due to the ongoing COVID-19 pandemic, which has affected the normal production and operation of some clients, leading to a slowdown in demand for products and services outside of COVID-19 related testing products[174]. - The company faces significant technical, talent, brand, and funding barriers, which create challenges for new entrants in the market[62].

Financial Performance - The company's revenue for Q3 2021 was ¥178,250,421.11, a decrease of 68.91% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2021 was ¥113,712,536.77, down 72.66% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥98,477,492.32, reflecting a decline of 76.21% compared to the previous year[4]. - Basic and diluted earnings per share for Q3 2021 were both ¥2.0067, a decrease of 75.39% year-on-year[7]. - Total operating revenue for the current period is 812,948,531.27 CNY, a decrease of approximately 24% compared to 1,068,535,711.45 CNY in the previous period[48]. - Net profit for the current period is 556,362,582.99 CNY, down from 750,594,220.68 CNY, reflecting a decrease of around 26%[51]. - The total comprehensive income attributable to the parent company was CNY 557,545,024.32, compared to CNY 752,495,618.77 in the previous period, reflecting a decrease of approximately 26%[54]. - Basic and diluted earnings per share were CNY 10.5195, down from CNY 14.7175 in the previous period, indicating a decline of about 29.8%[54]. Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥6,679,292,731.77, an increase of 355.92% from the end of the previous year[7]. - The company's total assets amounted to RMB 6,679,292,731.77, a significant increase from RMB 1,465,027,156.89 as of December 31, 2020[38]. - Total liabilities decreased to 95,959,539.44 CNY from 166,383,639.22 CNY, a reduction of approximately 42%[44]. - Total liabilities reached 166,383,639.22, down from 189,672,693.69, indicating a reduction of 23,289,054.47[69]. - Owner's equity increased significantly to 6,583,333,192.33 CNY, compared to 1,298,643,517.67 CNY, representing an increase of about 408%[47]. - Owner's equity totaled 1,298,643,517.67, remaining unchanged from the previous period[72]. Cash Flow - The company reported a net cash flow from operating activities of ¥455,852,218.88, down 15.55% year-on-year[4]. - Cash inflow from operating activities totaled CNY 872,847,387.20, an increase from CNY 800,081,034.60 in the previous period, representing a growth of approximately 9%[57]. - Cash outflow from operating activities was CNY 416,995,168.32, compared to CNY 260,311,528.93 in the previous period, showing an increase of about 60%[57]. - Cash inflow from investment activities was CNY 2,545,611,806.61, significantly higher than CNY 292,363,345.33 in the previous period, indicating a substantial increase[60]. - Cash outflow from investment activities totaled CNY 3,123,661,450.28, compared to CNY 742,079,800.52 in the previous period, marking an increase of approximately 320%[60]. - Net cash flow from financing activities was CNY 4,720,050,530.28, a significant improvement from a net outflow of CNY 2,900,000.00 in the previous period[60]. - The cash and cash equivalents at the end of the period amounted to CNY 4,654,977,849.90, compared to CNY 96,907,321.22 in the previous period, showing a substantial increase[60]. - The company reported a net increase in cash and cash equivalents of CNY 4,598,862,076.90, compared to CNY 86,627,000.35 in the previous period, indicating a strong cash position[60]. Investments and Expenses - R&D expenses surged to ¥32,116,971.18, an increase of 84.01%, indicating a significant boost in research and development investments[15]. - Investment income rose dramatically by 1,885.69% to ¥27,071,806.61, attributed to returns from matured financial products[15]. - Financial expenses decreased by 80.93% to ¥2,593,271.97, primarily due to currency exchange rate fluctuations[15]. - The company received government subsidies amounting to ¥1,050,000.00 in the current period[9]. - Other income grew by 196.21% to ¥3,353,594.12, largely from received listing subsidies[15]. Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[4]. - The company plans to use RMB 114,500.00 million of the excess raised funds to permanently supplement its working capital, as approved in the board and shareholder meetings[29]. - The company intends to use RMB 90,384,095.37 to replace self-raised funds previously invested in projects, including RMB 82,838,085.94 for the biological reagent R&D center and RMB 7,546,009.43 for issuance costs[33]. - The company has approved the use of up to RMB 320,000.00 million of temporarily idle raised funds for cash management, investing in high-security and liquid financial products for a period of 12 months[34]. - The company has signed an agreement to establish a wholly-owned subsidiary in the Taizhou Medical High-tech Industrial Park, enhancing its operational footprint[37]. Audit and Compliance - The company has not audited the third-quarter report, which may affect stakeholder confidence in the reported figures[72]. - The company is expected to continue monitoring its financial position closely in light of the recent adjustments in asset and liability totals[72].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥634,698,110.16, representing a 28.18% increase compared to ¥495,168,259.06 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2021 was ¥442,650,046.22, up 32.26% from ¥334,673,923.85 in the previous year[26]. - The basic earnings per share for the first half of 2021 were ¥8.6794, which is a 32.26% increase from ¥6.5622 in the same period last year[26]. - Operating profit for the first half of 2021 was ¥528,749,034.32, an increase of 35.3% compared to ¥391,163,462.78 in the same period of 2020[179]. - The company's total comprehensive income for the first half of 2021 was ¥443,731,854.77, compared to ¥335,906,628.85 in the same period of 2020[182]. Cash Flow and Assets - The net cash flow from operating activities increased significantly by 169.78%, reaching ¥390,173,692.51 compared to ¥144,628,395.61 in the same period last year[26]. - Cash and cash equivalents as of June 30, 2021, amounted to ¥145,312,733.18, an increase from ¥56,115,773.00 at the end of 2020[157]. - The company reported a net cash flow from operating activities of ¥387,039,912.91, compared to ¥99,730,971.72 in the previous year[199]. - Total cash inflow from operating activities was ¥710,198,902.01, compared to ¥286,525,831.83 in the previous year[195]. - The company experienced a net increase in cash and cash equivalents of ¥89,196,960.18, compared to ¥58,762,882.93 in the previous year[198]. Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥1,854,707,489.68, a 26.60% increase from ¥1,465,027,156.89 at the end of the previous year[26]. - The company's equity attributable to shareholders rose to ¥1,744,581,040.08, up from ¥1,298,643,517.67, marking an increase of around 34.3%[166]. - Total liabilities decreased to ¥110,126,449.60 from ¥166,383,639.22, indicating a reduction of approximately 33.7%[163]. - Accounts receivable decreased to ¥141,804,830.74, accounting for 7.65% of total assets, down from 13.26% the previous year, primarily due to improved collection[55]. - The trading financial assets increased to ¥1,380,175,561.87 from ¥1,072,708,285.69 year-over-year[157]. Revenue Breakdown - Revenue from non-epidemic virus-related business reached 177 million yuan, up 45.05% year-on-year[40]. - Revenue from epidemic virus-related business was 458 million yuan, an increase of 22.67% compared to the previous year[40]. - Revenue from the U.S. market accounted for 64.49% of total revenue during the reporting period, highlighting the importance of this market for the company[78]. - The company's revenue for the reporting period reached ¥634,698,110.16, representing a year-on-year increase of 28.18% due to growth in both pandemic-related and non-pandemic product sales[52]. Research and Development - R&D investment increased by 70.43% to ¥18,280,828.79, reflecting ongoing commitment to developing protein and antibody products[52]. - The company has developed a product library with over 6,000 protein reagents and approximately 13,000 antibody reagents, indicating strong R&D capabilities[46]. - The company has developed a series of core technology platforms to meet the diverse needs of biological research units[38]. - The company provides customized technical services for recombinant protein expression and purification, antibody development, and production[39]. Market and Competition - The company faces several risks, including performance decline, new product development risks, and intensified industry competition[6]. - The company has established stable partnerships with renowned research institutions and pharmaceutical companies, enhancing its brand and market reputation[50]. - The company has established a global market presence, with products sold in over 90 countries, enhancing its market competitiveness[48]. - The global biopharmaceutical research and life sciences market is expected to see continued investment growth due to increasing health concerns and government support[41]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[6]. - The company intends to invest in mergers and acquisitions of high-quality domestic and international enterprises to enhance its product line and technical capabilities[86]. - The company plans to continue independent research and development, aiming to enrich its existing product lines and enhance its technological capabilities[80]. - The company aims to develop high-quality diagnostic reagent raw materials based on its existing research capabilities in recombinant proteins and antibodies[84]. Compliance and Governance - The company has complied with environmental regulations and has not faced any significant administrative penalties during the reporting period[97]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[114]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[108]. - The half-year financial report has not been audited[110].